New Sivextro Gives Clinicians Options for Life-Threatening Skin Infections

SIVEXTRO (tedizolid phosphate) by Cubist
SIVEXTRO (tedizolid phosphate) by Cubist

Cubist announced that the FDA has approved Sivextro (tedizolid phosphate) for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI), including methicillin-resistant Staphylococcus aureus (MRSA).

The approval of Sivextro was based on two Phase 3 studies that met both primary and secondary endpoints. The studies showed that Sivextro 200mg once daily for 6 days was non-inferior to linezolid 600mg twice daily for 10 days.

RELATED: New Antibiotic Approved for Skin Infections, Including MRSA

Sivextro is a novel oxazolidinone antibacterial that binds to the 50S subunit of the bacterial ribosome resulting in inhibition of protein synthesis. Tedizolid inhibits bacterial protein synthesis through a mechanism of action different from that of other non-oxazolidinone class 13 antibacterial drugs; therefore, cross-resistance between tedizolid and other classes of antibacterial drugs is unlikely.

Sivextro will be available as 200mg strength tablets in 30-count bottles and 6-tablet blister packs, and as a 200mg single-dose vials in 10-count packages.

For more information call (844) CUBIST-CARES or visit